Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases

Journal of Heart and Lung Transplantation

Volumn 31, Issue 3, 2012, Pages 296-304

  Kremer, Brandon E ^a   Reshef, Ran ^a   Misleh, Jamal G ^b   Christie, Jason D ^b   Ahya, Vivek N ^b   Blumenthal, Nancy P ^b   Kotloff, Robert M ^b   Hadjiliadis, Denis ^b   Stadtmauer, Edward A ^a   Schuster, Stephen J ^a   Tsai, Donald E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

gastrointestinal tract; lung transplantation; post transplant lymphoproliferative disorder; PTLD

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DOXORUBICIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CYSTIC FIBROSIS; EISENMENGER COMPLEX; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GASTROINTESTINAL TRACT; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; OVERALL SURVIVAL; POLYMYOSITIS; POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; TREATMENT OUTCOME;

EID: 84857053238     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2011.10.013     Document Type: Article

References (47)

1. S. Wasson, M.N. Zafar, J. Best, H.K. Reddy Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience J Cardiovasc Pharmacol Ther 11 2006 77 83
2. S. Gottschalk, C.M. Rooney, H.E. Heslop Post-transplant lymphoproliferative disorders Annu Rev Med 56 2005 29 44 (Pubitemid 40299772)
3. A.W. Loren, D.E. Tsai Post-transplant lymphoproliferative disorder Clin Chest Med 26 2005 631 645 vii (Pubitemid 41563263)
4. D.A. Wigle, C. Chaparro, A. Humar, M.A. Hutcheon, C.K. Chan, S. Keshavjee Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation Transplantation 72 2001 1783 1786 (Pubitemid 33144232)
5. S. Paranjothi, R.D. Yusen, M.D. Kraus, J.P. Lynch, G.A. Patterson, E.P. Trulock Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases J Heart Lung Transplant 20 2001 1054 1063 (Pubitemid 32930110)
6. F.K. Buadi, M.R. Heyman, C.D. Gocke Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study Am J Hematol 82 2007 208 214 (Pubitemid 46363787)
7. N.A. Bakker, G.W. van Imhoff, E.A. Verschuuren Early onset post-transplant lymphoproliferative disease is associated with allograft localization Clin Transplant 19 2005 327 334 (Pubitemid 40711965)
8. B.D. Reams, H.P. McAdams, D.N. Howell, M.P. Steele, R.D. Davis, S.M. Palmer Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients Chest 124 2003 1242 1249 (Pubitemid 37290032)
9. van Loenhout KC, Groves SC, Galazka M, et al. Early outcomes using alemtuzumab induction in lung transplantation. Interact Cardiovasc Thorac Surg;10:1904.
10. H. Patel, D.T. Vogl, N. Aqui Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases Leuk Lymphoma 48 2007 885 891 (Pubitemid 47161559)
11. N.L. Harris, J.A. Ferry, S.H. Swerdlow Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop Semin Diagn Pathol 14 1997 8 14 (Pubitemid 27078881)
12. R. Reshef, S. Vardhanabhuti, M.R. Luskin Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder Am J Transplant 11 2011 336 347
13. L.J. Swinnen Diagnosis and treatment of transplant-related lymphoma Ann Oncol 11 Suppl 1 2000 45 48
14. D.E. Tsai, C.L. Hardy, J.E. Tomaszewski Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients Transplantation 71 2001 1076 1088 (Pubitemid 32448822)
15. T.E. Starzl, M.A. Nalesnik, K.A. Porter Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy Lancet 1 1984 583 587 (Pubitemid 14156511)
16. A.H. Blaes, B.A. Peterson, N. Bartlett, D.L. Dunn, V.A. Morrison Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial Cancer 104 2005 1661 1667 (Pubitemid 41437429)
17. R.L. Elstrom, C. Andreadis, N.A. Aqui Treatment of PTLD with rituximab or chemotherapy Am J Transplant 6 2006 569 576 (Pubitemid 43382145)
18. C. Knoop, A. Kentos, M. Remmelink Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission Clin Transplant 20 2006 179 187
19. J.F. Buell, T.G. Gross, M.J. Hanaway Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience Transplant Proc 37 2005 956 957 (Pubitemid 40590757)
20. P.P. Carbone, H.S. Kaplan, K. Musshoff, D.W. Smithers, M. Tubiana Report of the Committee on Hodgkin's Disease Staging Classification Cancer Res 31 1971 1860 1861
21. A.R. Padhani, L. Ollivier The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists Br J Radiol 74 2001 983 986 (Pubitemid 33121128)
22. C.D. Dinardo, D.E. Tsai Treatment advances in posttransplant lymphoproliferative disease Curr Opin Hematol 17 2010 368 374
23. M.J. Everly, R.D. Bloom, D.E. Tsai, J. Trofe Posttransplant lymphoproliferative disorder Ann Pharmacother 41 2007 1850 1858 (Pubitemid 350044348)
24. H.M. Kauffman, W.S. Cherikh, M.A. McBride, Y. Cheng, D.W. Hanto Post-transplant de novo malignancies in renal transplant recipients: the past and present Transpl Int 19 2006 607 620
25. S. Euvrard, J. Kanitakis, A. Claudy Skin cancers after organ transplantation N Engl J Med 348 2003 1681 1691 (Pubitemid 36459475)
26. L.J. Swinnen, M.R. Costanzo-Nordin, S.G. Fisher Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients N Engl J Med 323 1990 1723 1728
27. L.J. Swinnen, G.M. Mullen, T.J. Carr, M.R. Costanzo, R.I. Fisher Aggressive treatment for postcardiac transplant lymphoproliferation Blood 86 1995 3333 3340
28. L.F. Angel, T.H. Cai, E.Y. Sako, S.M. Levine Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center Ann Transplant 5 2000 26 30
29. R.M. Aris, D.M. Maia, I.P. Neuringer Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient Am J Respir Crit Care Med 154 1996 1712 1717 (Pubitemid 26424940)
30. T. Heller, C.B. Drachenberg, J.B. Orens, G.T. Fantry Primary posttransplant lymphoproliferative disorder of the gallbladder in a lung transplant patient presenting with acute cholecystitis Transplantation 69 2000 668 670 (Pubitemid 30129606)
31. J.I. Cohen, C.M. Bollard, R. Khanna, S. Pittaluga Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas Leuk Lymphoma 49 suppl 1 2008 27 34
32. D.A. Hale Biological effects of induction immunosuppression Curr Opin Immunol 16 2004 565 570 (Pubitemid 39165882)
33. J.S. Hawksworth, D. Leeser, R.M. Jindal, E. Falta, D. Tadaki, E.A. Elster New directions for induction immunosuppression strategy in solid organ transplantation Am J Surg 197 2009 515 524
34. E.R. Garrity Jr. , J. Villanueva, S.M. Bhorade, A.N. Husain, W.T. Vigneswaran Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody Transplantation 71 2001 773 777 (Pubitemid 32373693)
35. R. Lischke, J. Simonek, R. Davidova Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin Transplant Proc 39 2007 205 212 (Pubitemid 46175949)
36. J.C. Mullen, A. Oreopoulos, D.C. Lien A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation J Heart Lung Transplant 26 2007 504 510 (Pubitemid 46602005)
37. S. Caillard, C. Lelong, F. Pessione, B. Moulin Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry Am J Transplant 6 2006 2735 2742 (Pubitemid 44571695)
38. A.D. Kirk, W.S. Cherikh, M. Ring Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab Am J Transplant 7 2007 2619 2625 (Pubitemid 47561615)
39. W.S. Cherikh, H.M. Kauffman, M.A. McBride, J. Maghirang, L.J. Swinnen, D.W. Hanto Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation Transplantation 76 2003 1289 1293 (Pubitemid 37430713)
40. W. Bichari, M. Bartiromo, H. Mohey Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases Transplant Proc 41 2009 672 673
41. V. Pourfarziani, S. Taheri, M. Lessan-Pezeshki Lymphoma after living donor kidney transplantation: an Iranian multicenter experience Int Urol Nephrol 40 2008 1089 1094
42. G. Opelz, B. Dohler Lymphomas after solid organ transplantation: a collaborative transplant study report Am J Transplant 4 2004 222 230 (Pubitemid 38248525)
43. W.K. Kremers, H.C. Devarbhavi, R.H. Wiesner, R.A. Krom, W.R. Macon, T.M. Habermann Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival Am J Transplant 6 2006 1017 1024 (Pubitemid 44356653)
44. V. Leblond, F. Davi, F. Charlotte Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16 1998 2052 2059 (Pubitemid 28265040)
45. B.P. Nelson, M.A. Nalesnik, D.W. Bahler, J. Locker, J.J. Fung, S.H. Swerdlow Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 24 2000 375 385 (Pubitemid 30127473)
46. G. Dotti, R. Fiocchi, T. Motta Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant Transplantation 69 2000 827 833 (Pubitemid 30174106)
47. J. Grinyo, B. Charpentier, J.M. Pestana An integrated safety profile analysis of belatacept in kidney transplant recipients Transplantation 90 2010 1521 1527